[go: up one dir, main page]

WO2012001083A3 - Novel eprinomectin injectable compositions - Google Patents

Novel eprinomectin injectable compositions Download PDF

Info

Publication number
WO2012001083A3
WO2012001083A3 PCT/EP2011/060969 EP2011060969W WO2012001083A3 WO 2012001083 A3 WO2012001083 A3 WO 2012001083A3 EP 2011060969 W EP2011060969 W EP 2011060969W WO 2012001083 A3 WO2012001083 A3 WO 2012001083A3
Authority
WO
WIPO (PCT)
Prior art keywords
eprinomectin
novel
solvents
injectable compositions
parasiticide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/060969
Other languages
French (fr)
Other versions
WO2012001083A2 (en
Inventor
Hannelie Cilliers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceva Sante Animale SA
Original Assignee
Ceva Sante Animale SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale SA filed Critical Ceva Sante Animale SA
Priority to RU2013103140/15A priority Critical patent/RU2578036C2/en
Publication of WO2012001083A2 publication Critical patent/WO2012001083A2/en
Publication of WO2012001083A3 publication Critical patent/WO2012001083A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

An improved injectable parasiticide composition for treating infections caused by ectoparasites and endoparasites, wherein the formulation comprises a solvent system comprising polyethylene glycol and optionally other excipients and a pharmaceutically acceptable solvent or mixture of solvents and co-solvents, said novel formulation being capable of improving the bioavailability and residence time of the parasiticide in the treated non human mammals. Preferred compositions according to the invention comprise parasiticides which are macrocyclic lactones having poor liphophilic properties, such as for example eprinomectin.
PCT/EP2011/060969 2010-06-29 2011-06-29 Novel eprinomectin injectable compositions Ceased WO2012001083A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2013103140/15A RU2578036C2 (en) 2010-06-29 2011-06-29 New injectable compositions of eprinomectin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35966310P 2010-06-29 2010-06-29
US61/359,663 2010-06-29

Publications (2)

Publication Number Publication Date
WO2012001083A2 WO2012001083A2 (en) 2012-01-05
WO2012001083A3 true WO2012001083A3 (en) 2012-05-24

Family

ID=44629174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/060969 Ceased WO2012001083A2 (en) 2010-06-29 2011-06-29 Novel eprinomectin injectable compositions

Country Status (2)

Country Link
RU (1) RU2578036C2 (en)
WO (1) WO2012001083A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014098623A1 (en) * 2012-12-20 2014-06-26 Alleva Animal Health Limited Injectable eprinomectin formulation and anthelmintic use thereof
FI3052080T3 (en) * 2013-09-30 2025-08-22 Zoetis Services Llc Long-acting spiro-isoxazoline formulations
EP3023092A1 (en) 2014-11-20 2016-05-25 Ceva Sante Animale Eprinomectin parenteral compositions
CN114651961A (en) * 2022-03-25 2022-06-24 浙江科露宝食品有限公司 Medical formula food thickening component and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026895A1 (en) * 1996-01-29 1997-07-31 Gene Komer Avermectin formulation
US20070042013A1 (en) * 2005-08-19 2007-02-22 Soll Mark D Long acting injectable formulations
US20080027011A1 (en) * 2005-12-20 2008-01-31 Hassan Nached Homogeneous paste and gel formulations
WO2009070687A1 (en) * 2007-11-26 2009-06-04 Merial Limited Solvent systems for pour-on formulations for combating parasites

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (en) 1976-04-19 1984-07-16 Merck & Co Inc SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS
CA2233016C (en) 1995-09-25 2007-07-17 Ashmont Holdings Limited Anthelmintic macrocyclic lactone compositions
AR045142A1 (en) * 2003-07-30 2005-10-19 Novartis Ag BUEN SABOR DUCTILE MASTICABLE VETERINARY COMPOSITION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026895A1 (en) * 1996-01-29 1997-07-31 Gene Komer Avermectin formulation
US20070042013A1 (en) * 2005-08-19 2007-02-22 Soll Mark D Long acting injectable formulations
US20080027011A1 (en) * 2005-12-20 2008-01-31 Hassan Nached Homogeneous paste and gel formulations
WO2009070687A1 (en) * 2007-11-26 2009-06-04 Merial Limited Solvent systems for pour-on formulations for combating parasites

Also Published As

Publication number Publication date
WO2012001083A2 (en) 2012-01-05
RU2013103140A (en) 2014-08-10
RU2578036C2 (en) 2016-03-20

Similar Documents

Publication Publication Date Title
EA201492011A1 (en) ANHATIC PHARMACEUTICAL FORMULATIONS FOR LOCAL APPLICATION
HK1255102A1 (en) Heterocyclic compounds and uses thereof
MX382727B (en) BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND ITS USE
WO2008154642A3 (en) Antibacterial agents
WO2009111653A3 (en) Antiviral therapeutic agents
BR112018003595A2 (en) 6-6 bicyclic aromatic ring substituted nucleoside analogs for use as prmt5 inhibitors
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
EP3263135A4 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014019908A3 (en) Substituted pyrroles active as kinases inhibitors
BR112019024747A2 (en) fixed dose formulations
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
JO3611B1 (en) Cyclopenta (C (pyrrole 4,3 dihydro 1 H substituted [8,1]) antibacterial naphthyridinone
WO2019089676A8 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2012024405A3 (en) Curcumin compositions and uses thereof
WO2009071650A3 (en) Amide compounds as boosters of antivirals
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2012001083A3 (en) Novel eprinomectin injectable compositions
WO2012050641A3 (en) Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
AR064152A1 (en) ANTIBACTERIAL QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PREPARATION METHOD.
WO2013150550A3 (en) An improved process for the preparation of carbapenem antibiotic
HK1213806A1 (en) Method of preparing resin tinctures
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11737914

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012/13789

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013103140

Country of ref document: RU

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 11737914

Country of ref document: EP

Kind code of ref document: A2